Ratings by Rodman & Renshaw (Michael King Jr.)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/12/2026 | Hemab Therapeutics Holdings | COAG | New Coverage | Buy (N/A) |
31.62 (30.07) |
-4.9% | Details | |
| 9/28/2026 | Agenus Inc. | AGEN | New Coverage | Buy (N/A) |
8.54 (6.04) |
-29.27% | Details | |
| 8/31/2026 | QNTM | New Coverage | Buy (N/A) |
3.08 (2.47) |
-19.81% | Details | ||
| 7/30/2026 | Actuate Therapeutics | ACTU | New Coverage | Buy (N/A) |
1.08 (0.61) |
-43.52% | Details | |
| 7/7/2026 | Atossa Genetics | ATOS | New Coverage | Buy (N/A) |
2.28 (2.91) |
27.63% | Details | |
| 6/30/2026 | vTv Therapeutics | VTVT | New Coverage | Buy (N/A) |
36.27 (26.54) |
-26.83% | Details | |
| 6/15/2026 | Elicio Therapeutics | ELTX | Maintain | Buy (N/A) |
|
Details | ||
| 6/9/2026 | Kyntra Bio | KYNB | New Coverage | Buy (N/A) |
6.63 (4.85) |
-26.85% | Details | |
| 5/28/2026 | Bolt Biotherapeutics, Inc. | BOLT | New Coverage | Buy (N/A) |
5.28 (4.00) |
-24.24% | Details | |
| 5/11/2026 | Sana Biotechnology | SANA | New Coverage | Buy (N/A) |
3.51 (2.27) |
-35.33% | Details | |
| 4/15/2026 | TuHURA Biosciences | HURA | New Coverage | Buy (N/A) |
3.15 (1.76) |
-44.13% | Details | |
| 3/17/2026 | BioXcel Therapeutics | BTAI | New Coverage | Buy (N/A) |
1.54 (0.07) |
-95.45% | Details | |
| 3/9/2026 | Karyopharm Therapeutics | KPTI | New Coverage | Buy (N/A) |
8.77 (0.39) |
-95.55% | Details | |
| 3/9/2026 | Elicio Therapeutics | ELTX | New Coverage | Buy (N/A) |
11.63 (1.56) |
-86.59% | Details | |
| 1/13/2026 | Telomir Pharma | TELO | New Coverage | Buy (N/A) |
1.35 (1.05) |
-22.22% | Details | |
| 1/13/2026 | Ascentage Pharma Group | AAPG | New Coverage | Buy (N/A) |
28.38 (15.37) |
-45.84% | Details | |
| 1/13/2026 | Biomea Fusion Inc. | BMEA | New Coverage | Buy (N/A) |
1.46 (0.87) |
-40.41% | Details | |
| 1/13/2026 | BioAtla Inc. | BCAB | New Coverage | Buy (N/A) |
0.31 (1.74) |
461.29% | Details | |
| 1/13/2026 | Jasper Therapeutics | JSPR | New Coverage | Buy (N/A) |
1.48 (0.48) |
-67.57% | Details |
